Metabolic profiling of 3-nitropropionic acid early-stage huntingtons disease rat model using gas chromatography time-of-flight mass spectrometry

Journal of Proteome Research

Volumn 10, Issue 4, 2011, Pages 2079-2087

  Chang, Kai Lun ^a   New, Lee Sun ^a   Mal, Mainak ^a   Goh, Catherine W ^b   Aw, Chiu Cheong ^b   Browne, Edward R ^b   Chan, Eric C Y ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GLAXOSMITHKLINE   (Singapore)

Author keywords

3 nitropropionic acid; galantamine; Huntingtons disease; metabolic profiling; metabonomics; mitochondrial dysfunction; neurodegeneration; oxidative Stress

Indexed keywords

3 NITROPROPIONIC ACID; BIOLOGICAL MARKER; GALANTAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; GAS CHROMATOGRAPHY; GLUTATHIONE METABOLISM; HUNTINGTON CHOREA; MALE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RAT; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX II; GALANTAMINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUNTINGTON DISEASE; METABOLOME; METABOLOMICS; MITOCHONDRIA; NITRO COMPOUNDS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 79953681359     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr2000336     Document Type: Article

References (48)

1. The Huntingtons Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes Cell 1993, 72 (6) 971-83
2. Harris, G. J.; Pearlson, G. D.; Peyser, C. E.; Aylward, E. H.; Roberts, J.; Barta, P. E.; Chase, G. A.; Folstein, S. E. Putamen volume reduction on magnetic-resonance-imaging exceeds caudate changes in mild Huntingtons disease Ann. Neurol. 1992, 31 (1) 69-75
3. Kirkwood, S.; Su, J.; Conneally, P.; Foroud, T. Progression of symptoms in the early and middle stages of Huntington disease Arch. Neurol. 2001, 58 (2) 273
4. Calabresi, P.; Gubellini, P.; Picconi, B.; Centonze, D.; Pisani, A.; Bonsi, P.; Greengard, P.; Hipskind, R. A.; Borrelli, E.; Bernardi, G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine J. Neurosci. 2001, 21 (14) 5110-5120 (Pubitemid 32622936)
5. Maier, C. M.; Chan, P. H. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders Neuroscientist 2002, 8 (4) 323-334 (Pubitemid 34824016)
6. Browne, S. E.; Bowling, A. C.; MacGarvey, U.; Baik, M. J.; Berger, S. C.; Muqit, M. M. K.; Bird, E. D.; Beal, M. F. Oxidative damage and metabolic dysfunction in Huntingtons disease: Selective vulnerability of the basal ganglia Ann. Neurol. 1997, 41 (5) 646-653 (Pubitemid 27212659)
7. Gu, M.; Gash, M. T.; Mann, V. M.; JavoyAgid, F.; Cooper, J. M.; Schapira, A. H. V. Mitochondrial defect in Huntingtons disease on caudate nucleus Ann. Neurol. 1996, 39 (3) 385-389 (Pubitemid 26100764)
8. Lim, D.; Fedrizzi, L.; Tartari, M.; Zuccato, C.; Cattaneo, E.; Brini, M.; Carafoli, E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease J. Biol. Chem. 2008, 283 (9) 5780-5789
9. Cassarino, D. S.; Bennett, J. P. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration Brain Res. Rev. 1999, 29 (1) 1-25 (Pubitemid 29016078)
10. Van Houten, B.; Woshner, V.; Santos, J. H. Role of mitochondrial DNA in toxic responses to oxidative stress DNA Repair 2006, 5 (2) 145-152 (Pubitemid 43069515)
11. Trushina, E.; McMurray, C. T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases Neuroscience 2007, 145 (4) 1233-1248 (Pubitemid 46602738)
12. Ludolph, A. C.; He, F.; Spencer, P. S.; Hammerstad, J.; Sabri, M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin Can. J. Neurol. Sci. 1991, 18 (4) 492-498
13. Sawa, A.; Wiegand, G. W.; Cooper, J.; Margolis, R. L.; Sharp, A. H.; Lawler, J. F.; Greenamyre, J. T.; Snyder, S. H.; Ross, C. A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization Nat. Med. 1999, 5 (10) 1194-1198 (Pubitemid 29474426)
14. Jenkins, B. G.; Rosas, H. D.; Chen, Y. C. I.; Makabe, T.; Myers, R.; MacDonald, M.; Rosen, B. R.; Beal, M. F.; Koroshetz, W. J. H-1 NMR spectroscopy studies of Huntingtons disease-Correlations with CAG repeat numbers Neurology 1998, 50 (5) 1357-1365 (Pubitemid 28240352)
15. Koroshetz, W. J.; Jenkins, B. G.; Rosen, B. R.; Beal, M. F. Energy metabolism defects in Huntingtons disease and effects of coenzyme Q(10) Ann. Neurol. 1997, 41 (2) 160-165 (Pubitemid 27082096)
16. Panov, A. V.; Gutekunst, C. A.; Leavitt, B. R.; Hayden, M. R.; Burke, J. R.; Strittmatter, W. J.; Greenamyre, J. T. Early mitochondrial calcium defects in Huntingtons disease are a direct effect of polyglutamines Nat. Neurosci. 2002, 5 (8) 731-736 (Pubitemid 34827590)
17. Brouillet, E.; Jacquard, C.; Bizat, N.; Blum, D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntingtons disease J. Neurochem. 2005, 95 (6) 1521-1540 (Pubitemid 41804051)
18. Tsang, T. M.; Haselden, J. N.; Holmes, E. Metabonomic characterization of the 3-nitropropionic acid rat model of Huntingtons disease Neurochem. Res. 2009, 34 (7) 1261-1271
19. Portera-Cailliau, C.; Hedreen, J. C.; Price, D. L.; Koliatsos, V. E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models J. Neurosci. 1995, 15 (5 Pt. 2) 3775-87
20. Ezoulin, M. J. M.; Ombetta, J. E.; Dutertre-Catella, H.; Warnet, J. M.; Massicot, F. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells Neurotoxicology 2008, 29 (2) 270-277
21. Park, J. E.; Lee, S. T.; Im, W. S.; Chu, K.; Kim, M. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntingtons disease Neurosci. Lett. 2008, 448 (1) 143-147
22. Petrikis, P.; Andreou, C.; Piachas, A.; Bozikas, V. P.; Karavatos, A. Treatment of Huntingtons disease with galantamine Int. Clin. Psychopharmacol. 2004, 19 (1) 49-50
23. Chen, C. M.; Wu, Y. R.; Cheng, M. L.; Liu, J. L.; Lee, Y. M.; Lee, P. W.; Soong, B. W.; Chiu, D. T. Y. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntingtons disease patients Biochem. Biophys. Res. Commun. 2007, 359 (2) 335-340
24. Klepac, N.; Relja, M.; Klepac, R.; Hecimovic, S.; Babic, T.; Trkulja, V. Oxidative stress parameters in plasma of Huntingtons disease patients, asymptomatic Huntingtons disease gene carriers and healthy subjects J. Neurol. 2007, 254 (12) 1676-1683
25. Keun, H. C.; Athersuch, T. J. Application of metabonomics in drug development Pharmacogenomics 2007, 8 (7) 731-41 (Pubitemid 47288974)
26. Kumar, P.; Kumar, A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntingtons disease like symptoms: Possible behavioural, biochemical and cellular alterations Eur. J. Pharmacol. 2009, 615 (1-3) 91-101
27. Kumar, P.; Kumar, A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33 (1) 100-108
28. Tunez, I.; Tasset, I.; Pérez-De La Cruz, V.; Santamaría, A. 3-Nitropropionic acid as a tool to study the mechanisms involved in huntingtons disease: past, present and future Molecules 2010, 15 (2) 878-916
29. Bains, J.; Shaw, C. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death Brain Res. Brain Res, Rev. 1997, 25 (3) 335
30. Dringen, R.; Hamprecht, B. Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures J. Neurochem. 1996, 67 (4) 1375
31. Dringen, R.; Verleysdonk, S.; Hamprecht, B.; Willker, W.; Leibfritz, D.; Brand, A. Metabolism of glycine in primary astroglial cells: synthesis of creatine, serine, and glutathione J. Neurochem. 1998, 70 (2) 835
32. Mao, Z.; Choo, Y. S.; Lesort, M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntingtons disease knock-in striatal cells Eur. J. Neurosci. 2006, 23 (7) 1701-10
33. Tkac, I.; Dubinsky, J.; Keene, C.; Gruetter, R.; Low, W. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo1H NMR spectroscopy J. Neurochem. 2007, 100 (5) 1397-1406
34. Fox, J. H.; Barber, D. S.; Singh, B.; Zucker, B.; Swindell, M. K.; Norflus, F.; Buzescu, R.; Chopra, R.; Ferrante, R. J.; Kazantsev, A.; Hersch, S. M. Cystamine increases L-cysteine levels in Huntingtons disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation J. Neurochem. 2004, 91 (2) 413-22 (Pubitemid 39363440)
35. Guillot, N.; Debard, C.; Calzada, C.; Vidal, H.; Lagarde, M.; Vericel, E. Effects of docosahexaenoic acid on some megakaryocytic cell gene expression of some enzymes controlling prostanoid synthesis Biochem. Biophys. Res. Commun. 2008, 372 (4) 924-928
36. Hashimoto, M.; Hossain, S.; Shimada, T.; Sugioka, K.; Yamasaki, H.; Fujii, Y.; Ishibashi, Y.; Oka, J. I.; Shido, O. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimers disease model rats J. Neurochem. 2002, 81 (5) 1084-1091 (Pubitemid 34809291)
37. Innis, S. M. Dietary (n-3) fatty acids and brain development J. Nutr. 2007, 137 (4) 855-859 (Pubitemid 46596878)
38. Shohami, E.; Beit-Yannai, E.; Horowitz, M.; Kohen, R. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome J. Cereb. Blood Flow Metab. 1997, 17 (10) 1007
39. Reiter, R. Oxidative processes and antioxidative defense mechanisms in the aging brain FASEB J. 1995, 9 (7) 526
40. Patra, R.; Swarup, D.; Dwivedi, S. Antioxidant effects of alpha tocopherol, ascorbic acid and L-methionine on lead induced oxidative stress to the liver, kidney and brain in rats Toxicology 2001, 162 (2) 81
41. Briere, J. J.; Favier, J.; El Ghouzzi, V.; Djouadi, F.; Benit, P.; Gimenez, A. P.; Rustin, P. Succinate dehydrogenase deficiency in human Cell. Mol. Life Sci. 2005, 62 (19-20) 2317-2324 (Pubitemid 41500547)
42. Kamboj, S.; Kumar, V.; Kamboj, A.; Sandhir, R. Mitochondrial oxidative stress and dysfunction in rat brain induced by carbofuran exposure Cell. Mol. Neurobiol. 2008, 28 (7) 961-969
43. Brouillet, E.; Guyot, M. C.; Mittoux, V.; Altairac, S.; Conde, F.; Palfi, S.; Hantraye, P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat J. Neurochem. 1998, 70 (2) 794-805 (Pubitemid 28079371)
44. Beal, M. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 1992, 31 (2) 119-130
45. Sloviter, H.; Shimkin, P.; Suhara, K. Glycerol as a substrate for brain metabolism Nature 1966, 210, 1334-1336
46. Badaut, J.; Regli, L. Distribution and possible roles of aquaporin 9 in the brain Neuroscience 2004, 129 (4) 971-981 (Pubitemid 39556248)
47. Beal, M. F.; Brouillet, E.; Jenkins, B. G.; Ferrante, R. J.; Kowall, N. W.; Miller, J. M.; Storey, E.; Srivastava, R.; Rosen, B. R.; Hyman, B. T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid J. Neurosci. 1993, 13 (10) 4181-4192 (Pubitemid 23299942)
48. Ouary, S.; Bizat, N.; Altairac, S.; Menetrat, H.; Mittoux, V.; Conde, F.; Hantraye, P.; Brouillet, E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neuroprotection studies Neuroscience 2000, 97 (3) 521-530 (Pubitemid 30320758)